search
Back to results

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)

Primary Purpose

Lymphoma, Non-Hodgkin, Hodgkin Disease

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
Relatlimab
Nivolumab
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lymphoma, Non-Hodgkin focused on measuring Pediatric, Lymphoma, Non-Hodgkin, Hodgkin Disease, Relatlimab, Nivolumab, Lymphocyte Activation Gene-3, Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal B-cell Lymphoma, Lymphoma, Large-Cell, Anaplastic

Eligibility Criteria

undefined - 30 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Pathologically confirmed high-risk recurrent/relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), after non-response to or failure of first-line standard therapy prior to high-dose chemotherapy/autologous stem cell transplant (HDCT/ASCT)
  • Pathologically confirmed high-risk, R/R non-Hodgkin lymphoma (NHL) after failure or non-response to first-line therapy, including but not limited to diffuse large B-cell lymphoma (DLBCL), anaplastic large cell lymphoma (ALCL) and primary mediastinal B-cell lymphoma
  • Pathologically confirmed recurrent cHL or NHL
  • Must have measurable [18F]fluorodeoxyglucose-positron emission tomography-computed tomography (FDG-PET-CT) positive disease in both cHL and NHL cohorts

Exclusion Criteria:

  • Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies
  • Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents
  • Prior autologous stem cell transplantation (HDCT/ASCT)
  • History of allogeneic bone marrow transplantation and with active graft versus host disease (GVHD) and prior history of Grade > 2 GVHD

Other protocol-defined inclusion/exclusion criteria apply

Sites / Locations

  • Phoenix Childrens Hospital PCH - Phoenix Childrens Medical Group - Hematology OncologyRecruiting
  • Stanford University - Lucile Packard Childrens Hospital LPCHRecruiting
  • Yale UniversityRecruiting
  • Nemours Childrens Hospital
  • Golisano Children's Hospital of Southwest FloridaRecruiting
  • AdventHealth
  • St. Mary's Medical Center
  • University of Minnesota Medical School - Masonic Childrens HospitalRecruiting
  • University of Mississippi Medical CenterRecruiting
  • Siteman Cancer Center - Washington University Medical Campus Location
  • Hackensack University Medical Center HUMC - The Joseph M. Sanzari Childrens Hospital - Children's Cancer Institute
  • Montefiore Medical Center
  • Columbia University Medical Center
  • New York Medical CollegeRecruiting
  • Penn State Health Milton S. Hershey Medical Center - Penn State Children's Hospital
  • Vanderbilt-Ingram Cancer CenterRecruiting
  • Dell Children's Medical Center of Central Texas (DCMC) - Strictly Pediatrics Subspecialty Center
  • CHRISTUS Santa Rosa Childrens Hospital CSRCH - The Howard A. Britton M.D. Childrens Cancer and Blood Disorders Center
  • UW Health - American Family Children's Hospital Pediatric Bone Marrow Transplant Clinic
  • Local Institution - 0037Recruiting
  • Local Institution - 0039Recruiting
  • Local Institution - 0042Recruiting
  • Local Institution - 0063Recruiting
  • Local Institution - 0048Recruiting
  • Local Institution - 0033
  • Local Institution - 0067
  • Local Institution - 0021Recruiting
  • Local Institution - 0034
  • Local Institution - 0018Recruiting
  • Local Institution - 0006Recruiting
  • Local Institution - 0047
  • Local Institution - 0022
  • Local Institution - 0052
  • Local Institution - 0056
  • Local Institution - 0015
  • Local Institution - 0028
  • Local Institution - 0036
  • Local Institution - 0008
  • Local Institution - 0051
  • Local Institution - 0041
  • Local Institution - 0010
  • Local Institution - 0007Recruiting
  • Local Institution - 0040Recruiting
  • Local Institution - 0005Recruiting
  • Local Institution - 0001Recruiting
  • Local Institution - 0070
  • Local Institution - 0043Recruiting
  • Local Institution - 0013
  • Local Institution - 0065
  • Local Institution - 0002
  • Local Institution - 0004Recruiting
  • Local Institution - 0057Recruiting
  • Local Institution - 0062Recruiting
  • Local Institution - 0046Recruiting
  • Local Institution - 0009
  • Local Institution - 0069
  • Local Institution - 0030Recruiting
  • Local Institution - 0058Recruiting
  • Local Institution - 0044
  • Local Institution - 0055Recruiting
  • Local Institution - 0045Recruiting
  • Local Institution - 0011
  • Local Institution - 0038
  • Local Institution - 0023Recruiting
  • Local Institution - 0049Recruiting
  • Local Institution - 0054
  • Local Institution - 0003
  • Local Institution - 0050
  • Local Institution - 0053
  • Local Institution - 0031
  • Local Institution - 0068

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Relatlimab + Nivolumab

Arm Description

Outcomes

Primary Outcome Measures

Incidence of dose-limiting toxicities (DLTs)
Maximum tolerated dose or Recommended phase 2 dose (MTD/RP2D)
Number of participants with Adverse Events (AEs)
Number of participants with serious adverse events (SAEs)
Number of participants with AEs leading to discontinuation
Number of deaths
Number of participants with clinical laboratory abnormalities
Maximum observed plasma concentration (Cmax)
Trough observed concentration (Ctrough)
Time of maximum observed plasma concentration (Tmax)
Area Under the Curve within a dosing interval (AUC(TAU))
Complete Metabolic Response (CMR) Rate defined as the proportion of all response-evaluable participants who achieve the best response of CMR using Lugano 2014 criteria

Secondary Outcome Measures

Number of participants with AEs
Number of participants with SAEs
Number of participants with AEs leading to discontinuation
Number of deaths
Number of participants with clinical laboratory abnormalities
Overall Response Rate (ORR) defined as the proportion of all response- evaluable participants who achieve a best response of CMR or partial metabolic response (PMR) using the Lugano 2014 classification

Full Information

First Posted
February 15, 2022
Last Updated
October 11, 2023
Sponsor
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT05255601
Brief Title
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Acronym
RELATIVITY-069
Official Title
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 13, 2022 (Actual)
Primary Completion Date
July 5, 2028 (Anticipated)
Study Completion Date
July 5, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphoma, Non-Hodgkin, Hodgkin Disease
Keywords
Pediatric, Lymphoma, Non-Hodgkin, Hodgkin Disease, Relatlimab, Nivolumab, Lymphocyte Activation Gene-3, Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal B-cell Lymphoma, Lymphoma, Large-Cell, Anaplastic

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
68 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Relatlimab + Nivolumab
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Relatlimab
Other Intervention Name(s)
BMS-986016
Intervention Description
Specified Dose on Specified Days
Intervention Type
Drug
Intervention Name(s)
Nivolumab
Other Intervention Name(s)
BMS-936558
Intervention Description
Specified Dose on Specified Days
Primary Outcome Measure Information:
Title
Incidence of dose-limiting toxicities (DLTs)
Time Frame
Up to 135 days following last dose
Title
Maximum tolerated dose or Recommended phase 2 dose (MTD/RP2D)
Time Frame
Up to 135 days following last dose
Title
Number of participants with Adverse Events (AEs)
Time Frame
Up to 135 days following last dose
Title
Number of participants with serious adverse events (SAEs)
Time Frame
Up to 135 days following last dose
Title
Number of participants with AEs leading to discontinuation
Time Frame
Up to 135 days following last dose
Title
Number of deaths
Time Frame
Up to 135 days following last dose
Title
Number of participants with clinical laboratory abnormalities
Time Frame
Up to 135 days following last dose
Title
Maximum observed plasma concentration (Cmax)
Time Frame
Up to 96 weeks
Title
Trough observed concentration (Ctrough)
Time Frame
Up to 96 weeks
Title
Time of maximum observed plasma concentration (Tmax)
Time Frame
Up to 96 weeks
Title
Area Under the Curve within a dosing interval (AUC(TAU))
Time Frame
Up to 96 weeks
Title
Complete Metabolic Response (CMR) Rate defined as the proportion of all response-evaluable participants who achieve the best response of CMR using Lugano 2014 criteria
Time Frame
Up to 2 years from the last treatment of last participant
Secondary Outcome Measure Information:
Title
Number of participants with AEs
Time Frame
Up to 135 days following last dose
Title
Number of participants with SAEs
Time Frame
Up to 135 days following last dose
Title
Number of participants with AEs leading to discontinuation
Time Frame
Up to 135 days following last dose
Title
Number of deaths
Time Frame
Up to 135 days following last dose
Title
Number of participants with clinical laboratory abnormalities
Time Frame
Up to 135 days following last dose
Title
Overall Response Rate (ORR) defined as the proportion of all response- evaluable participants who achieve a best response of CMR or partial metabolic response (PMR) using the Lugano 2014 classification
Time Frame
Up to 2 years from the last treatment of last participant

10. Eligibility

Sex
All
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pathologically confirmed high-risk recurrent/relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), after non-response to or failure of first-line standard therapy prior to a definitive therapy e.g.high-dose chemotherapy/autologous stem cell transplant (HDCT/ASCT) Participants with pathologically confirmed R/R NHL after failure or non-response to second line therapy, including but not limited to primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal gray zone lymphoma (MGZL), anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma (PTCL). Participants must have measurable PET positive disease in both cHL and NHL cohorts. Exclusion Criteria: Aggressive B-cell lymphomas subtypes including Burkitt lymphoma (BL), lymphoblastic lymphoma, and NK/T-cell lymphoma/leukemia. Primary CNS lymphoma of the brain or spinal cord, and secondary CNS lymphoma (ie, from systemic non-Hodgkin lymphoma) involving the brain, spinal cord, or with leptomeningeal seeding. Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents Prior autologous stem cell transplantation (HDCT/ASCT) History of allogeneic bone marrow transplantation. Other protocol-defined inclusion/exclusion criteria apply
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
BMS Study Connect Contact Center www.BMSStudyConnect.com
Phone
855-907-3286
Email
Clinical.Trials@bms.com
First Name & Middle Initial & Last Name or Official Title & Degree
First line of the email MUST contain NCT # and Site #.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Phoenix Childrens Hospital PCH - Phoenix Childrens Medical Group - Hematology Oncology
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Henry, Site 0024
Phone
602-933-2492
Facility Name
Stanford University - Lucile Packard Childrens Hospital LPCH
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lianna Marks, Site 0035
Phone
000-000-0000
Facility Name
Yale University
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephanie Massaro, Site 0032
Facility Name
Nemours Childrens Hospital
City
Wilmington
State/Province
Delaware
ZIP/Postal Code
19803
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emi Caywood, Site 0061
Phone
302-651-5500
Facility Name
Golisano Children's Hospital of Southwest Florida
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33908
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emad Salman, Site 0066
Facility Name
AdventHealth
City
Orlando
State/Province
Florida
ZIP/Postal Code
32804
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthew Henderson, Site 0017
Facility Name
St. Mary's Medical Center
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33407
Country
United States
Individual Site Status
Withdrawn
Facility Name
University of Minnesota Medical School - Masonic Childrens Hospital
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55454
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Gordon, Site 0025
Phone
707-651-2577
Facility Name
University of Mississippi Medical Center
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39216
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Betty Herrington, Site 0020
Phone
601-984-5220
Facility Name
Siteman Cancer Center - Washington University Medical Campus Location
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robert Hayashi, Site 0012
Phone
314-454-6018
Facility Name
Hackensack University Medical Center HUMC - The Joseph M. Sanzari Childrens Hospital - Children's Cancer Institute
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Burton Appel, Site 0071
Phone
201-487-7340
Facility Name
Montefiore Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alice Lee, Site 0016
Phone
212-305-5808
Facility Name
Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nobuko Hijiya, Site 0060
Phone
773-880-4562
Facility Name
New York Medical College
City
Valhalla
State/Province
New York
ZIP/Postal Code
10595
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mitchell Cairo, Site 0059
Facility Name
Penn State Health Milton S. Hershey Medical Center - Penn State Children's Hospital
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Valerie Brown, Site 0019
Phone
215-805-5247
Facility Name
Vanderbilt-Ingram Cancer Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Debra Friedman, Site 0014
Phone
615-936-1762
Facility Name
Dell Children's Medical Center of Central Texas (DCMC) - Strictly Pediatrics Subspecialty Center
City
Austin
State/Province
Texas
ZIP/Postal Code
78723
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shannon Cohn, Site 0029
Phone
512-628-1900
Facility Name
CHRISTUS Santa Rosa Childrens Hospital CSRCH - The Howard A. Britton M.D. Childrens Cancer and Blood Disorders Center
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78207
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Timothy Griffin, Site 0026
Phone
210-704-4275
Facility Name
UW Health - American Family Children's Hospital Pediatric Bone Marrow Transplant Clinic
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0037
City
Randwick
State/Province
New South Wales
ZIP/Postal Code
2031
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0037
Facility Name
Local Institution - 0039
City
South Brisbane
State/Province
Queensland
ZIP/Postal Code
4101
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0039
Facility Name
Local Institution - 0042
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0042
Facility Name
Local Institution - 0063
City
Angers
State/Province
Angers Cedex 9
ZIP/Postal Code
49933
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0063
Facility Name
Local Institution - 0048
City
Bordeaux
ZIP/Postal Code
33076
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0048
Facility Name
Local Institution - 0033
City
Caen
ZIP/Postal Code
14033
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0033
Facility Name
Local Institution - 0067
City
La Tronche
ZIP/Postal Code
38700
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0067
Facility Name
Local Institution - 0021
City
Lyon
ZIP/Postal Code
69373 Cedex 08
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0021
Facility Name
Local Institution - 0034
City
Marseille
ZIP/Postal Code
13385
Country
France
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0018
City
Montpellier
ZIP/Postal Code
34295
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0018
Facility Name
Local Institution - 0006
City
Paris
ZIP/Postal Code
75571
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0006
Facility Name
Local Institution - 0047
City
Paris
ZIP/Postal Code
75935
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0047
Facility Name
Local Institution - 0022
City
Rennes
ZIP/Postal Code
35203
Country
France
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0052
City
Strasbourg
ZIP/Postal Code
67000
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0052
Facility Name
Local Institution - 0056
City
Aachen
ZIP/Postal Code
52074
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0015
City
Berlin
ZIP/Postal Code
13353
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0028
City
Giessen
ZIP/Postal Code
35392
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0036
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0008
City
Muenster
ZIP/Postal Code
48149
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0051
City
Munich
ZIP/Postal Code
80337
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0041
City
Pavia
State/Province
PV
ZIP/Postal Code
27100
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0041
Facility Name
Local Institution - 0010
City
Aviano
ZIP/Postal Code
33081
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0010
Facility Name
Local Institution - 0007
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0007
Facility Name
Local Institution - 0040
City
Florence
ZIP/Postal Code
50139
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0040
Facility Name
Local Institution - 0005
City
Genoa
ZIP/Postal Code
16147
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0005
Facility Name
Local Institution - 0001
City
Milano
ZIP/Postal Code
20133
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0001
Facility Name
Local Institution - 0070
City
Milan
ZIP/Postal Code
20162
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0070
Facility Name
Local Institution - 0043
City
Monza
ZIP/Postal Code
20900
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0043
Facility Name
Local Institution - 0013
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0013
Facility Name
Local Institution - 0065
City
Padova
ZIP/Postal Code
35128
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0065
Facility Name
Local Institution - 0002
City
Roma
ZIP/Postal Code
165
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0002
Facility Name
Local Institution - 0004
City
Turin
ZIP/Postal Code
10126
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0004
Facility Name
Local Institution - 0057
City
Utrecht
ZIP/Postal Code
3584 CS
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0057
Facility Name
Local Institution - 0062
City
Pamplona
State/Province
Navarra
ZIP/Postal Code
31008
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0062
Facility Name
Local Institution - 0046
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0046
Facility Name
Local Institution - 0009
City
Barcelona
ZIP/Postal Code
8026
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0009
Facility Name
Local Institution - 0069
City
Esplugues de Llobregat
ZIP/Postal Code
8950
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0069
Facility Name
Local Institution - 0030
City
Madrid
ZIP/Postal Code
28009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0030
Facility Name
Local Institution - 0058
City
Madrid
ZIP/Postal Code
28027
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0058
Facility Name
Local Institution - 0044
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0044
Facility Name
Local Institution - 0055
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0055
Facility Name
Local Institution - 0045
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0045
Facility Name
Local Institution - 0011
City
Santander
ZIP/Postal Code
39008
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0011
Facility Name
Local Institution - 0038
City
Sevilla
ZIP/Postal Code
41009
Country
Spain
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0023
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0023
Facility Name
Local Institution - 0049
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0049
Facility Name
Local Institution - 0054
City
London
State/Province
Londonderry
ZIP/Postal Code
NW1 2PG
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0054
Facility Name
Local Institution - 0003
City
Nottingham
State/Province
Nottinghamshire
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0003
Facility Name
Local Institution - 0050
City
Bristol
State/Province
Somerset
ZIP/Postal Code
BS2 8BJ
Country
United Kingdom
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0053
City
Sutton
State/Province
Surrey
ZIP/Postal Code
SM2 5PT
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0053
Facility Name
Local Institution - 0031
City
Birmingham
State/Province
West Midlands
ZIP/Postal Code
B4 6NH
Country
United Kingdom
Individual Site Status
Withdrawn
Facility Name
Local Institution - 0068
City
Newcastle upon Tyne
ZIP/Postal Code
NE1 4LP
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 0068

12. IPD Sharing Statement

Links:
URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Description
BMS Clinical Trial Information
URL
https://www.bmsstudyconnect.com/us/en/home.html
Description
BMS Clinical Trial Patient Recruiting

Learn more about this trial

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

We'll reach out to this number within 24 hrs